Global Cardiac Ablation Market

Cardiac Ablation Market Size, Share, Growth Analysis, By Product(Radiofrequency (RF), Ablators, Electrical ablators, Cryoablation devices), By Application(Atrial fibrillation & flutter, Tachycardia, and Others), By Approach(Catheter-based, and Open/Surgical), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35A2459 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 92 | Figures: 66

Cardiac Ablation Market Insights

Cardiac Ablation Market size was valued at USD 1.29 billion in 2021 and is poised to grow from USD 1.45 billion in 2022 to USD 3.70 billion by 2030, growing at a CAGR of 14.2% in the forecast period (2023-2030).

Elevated caffeine intake, sedentary lifestyle adoption, excessive alcohol and tobacco consumption, substance misuse, and smoking tendencies are anticipated contributors to the escalating prevalence of cardiac disorders. The World Health Organization (WHO) reports an annual toll of over 1.9 million global deaths linked to tobacco-induced cardiac ailments. The American Heart Association (AHA) estimates that cardiovascular diseases result in nearly 800,000 annual fatalities in the U.S., with 20% attributed to cigarette smoking. Technological progress and heightened awareness of ablation device treatments are propelling market growth.

The Cardiac Ablation sector experienced a moderate setback due to the COVID-19 pandemic, stemming from healthcare facility disruptions and treatment availability challenges. Governments have introduced measures to bolster the industry, while major corporations have pioneered novel strategies and technologies to stabilize operations, ultimately fostering significant market expansion in the projected period.

Cardiac arrhythmia, with multifaceted origins, encompasses factors like pre-existing medical conditions (e.g., diabetes, hypertension), mental stress, heart disorders, and advanced age, alongside lifestyle-associated aspects such as smoking, alcohol, drug misuse, excessive caffeine, and dietary supplements. Cardiac ablation serves extensive purposes in cardiac rhythm management, open surgery, and other domains.

US Cardiac Ablation Market is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Cardiac Ablation Market size was valued at USD 1.29 billion in 2021 and is poised to grow from USD 1.45 billion in 2022 to USD 3.70 billion by 2030, growing at a CAGR of 14.2% in the forecast period (2023-2030).

The competitive landscape of the Cardiac Ablation market is characterized by intense rivalry among prominent players striving to innovate and capture a larger market share. Leading medical device companies such as Medtronic, Biosense Webster (a subsidiary of Johnson & Johnson), Boston Scientific Corporation, and Abbott Laboratories dominate the market with their extensive product portfolios and strong presence. These companies compete through continuous research and development, technological advancements, and strategic acquisitions to offer cutting-edge cardiac ablation solutions. 'Medtronic - USA', 'Biosense Webster (a subsidiary of Johnson & Johnson) - USA', 'Boston Scientific Corporation - USA', 'Abbott Laboratories - USA', 'AtriCure, Inc. - USA', 'MicroPort Scientific Corporation - China', 'St. Jude Medical, Inc. (now part of Abbott) - USA', 'Biotronik SE & Co. KG - Germany', 'Stereotaxis, Inc. - USA', 'Osypka Medical GmbH – Germany'

Technological breakthroughs are enhancing the effectiveness and safety of cardiac ablation procedures, attracting both patients and healthcare providers.

Minimally Invasive Procedures: There's a growing preference for minimally invasive techniques, reducing patient discomfort, hospital stays, and recovery time.

Anticipated to hold the predominant share of revenue in the cardiac ablation market throughout the forecast period, North America's prominence stems from its robust presence of leading pharmaceutical and medical equipment entities. A surge in clinical trials, favorable healthcare reimbursement policies, and substantial investments in the advancement of cardiac ablators collectively bolster the revenue trajectory in the region. The augmentation is further accentuated by a burgeoning array of product launches infused with cutting-edge technological innovations.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Cardiac Ablation Market

Report ID: SQMIG35A2459

$5,300
BUY NOW GET FREE SAMPLE